| 1. |
WHO/Epilepsy. http://www.who.int/mental_health/neurology/epilepsy/en/.
|
| 2. |
GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol, 2017, 16(11): 877-897.
|
| 3. |
Loscher W, Klitgaard H, Twyman RE, et al. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov, 2013, 12(10): 757-776.
|
| 4. |
Veiby G, Daltveit AK, Engelsen BA, et al. Fetal growth restriction and birth defects with newer and olderantiepileptic drugs during pregnancy. J Neurol, 2014, 261(3): 579-588.
|
| 5. |
Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK epilepsyand pregnancy register. J Neurol Neurosurg Psychiatry, 2006, 77(2): 193-198.
|
| 6. |
Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenitalmalformation outcomes in the child. Cochrane Database of Sys Rev, 2016, 11: CD010224.
|
| 7. |
Hunt S, Craig J, Russell A, et al. Levetiracetam inpregnancy: Preliminary experience from the UK epilepsy and pregnancy register. Neurology, 2006, 67(10): 1876-1879.
|
| 8. |
Longo B, Forinash AB, Murphy JA. Levetiracetam use in pregnancy. Ann Pharmacother, 2009, 43(10): 1692-1695.
|
| 9. |
Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and ireland epilepsy and pregnancy registers. Neurology, 2013, 80(4): 400-405.
|
| 10. |
Vajda FJ, O’Brien TJ, Lander CM, et al. The teratogenicity of the newer antiepileptic drugs-an update. Acta Neurol Scand, 2014, 130(4): 234-238.
|
